Healionics has developed a safer, more reliable means of dialysis access for patients with kidney failure. Our FDA Breakthrough-designated STARgraft vascular graft (synthetic blood vessel) has demonstrated superior 24-month clinical results showing resistance to both occlusion and infection -- the two primary causes of failure in on-market grafts. The company has 33 issued patents and a diverse product pipeline leveraging our core biomaterial technology to create novel implantable devices in additional cardiovascular, dialysis access, and general surgery applications. Comparable exits in dialysis access have been pre-revenue with average valuation of $500M.
Healionics is raising a $5M preferred equity round, led by Keiretsu Capital, to support the STARgraft pivotal clinical trial, FDA approval, and potential exit.
This session provides an opportunity for RVC portfolio company, Healionics, to update existing RVC Investors while engaging those interested in the current follow-on investment.
The RVC Deep Dive is a 90 minute virtual meeting held between company executive leadership, RVC Investors, and RVC staff. The purpose of this meeting is to cover all major due diligence questions such as business strategy, team, product, competition, IP, market, traction, key risks, and exit strategy.
The structure of the meeting is as follows:
- Company Pitch (15 minutes)
- Guided Q&A w/ Investors (45 minutes)
- Investor Only Discussion (30 minutes)
To attend, you must be an accredited investor (net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 together with his or her spouse if married] and have the expectation to make the same amount this year). We do not require a minimum investment.
Want to learn more? Please visit our main website: